β-thalassemia in Germany - Results of the cooperative β-thalassemia study;β-thalassamie in Deutschland - Ergebnisse der kooperativen β- thalassamie-studie

Klinische Padiatrie

Volumn 211, Issue 6, 1999, Pages 431-437

  Cario, Holger ^a   Stahnke, Karsten ^b   Kohne, Elisabeth ^a  

^a UNIVERSITY HOSPITAL ULM   (Germany)

^b NONE

Author keywords

Hemosiderosis; Observational; Study; Thalassemia; Transfusion

Indexed keywords

ADOLESCENT; ADULT; BETA THALASSEMIA; BLOOD TRANSFUSION; CHILD; FEMALE; GERMANY; HEMOSIDEROSIS; HUMAN; HYPOGONADISM; HYPOTHYROIDISM; LIVER DISEASE; MAJOR CLINICAL STUDY; MALE; PREVALENCE; REVIEW; AGE; ARTICLE; BLOOD; CLINICAL TRIAL; ETHNIC GROUP; INCIDENCE; INFANT; METHODOLOGY; MULTICENTER STUDY; PLASMAPHERESIS; PRESCHOOL CHILD; STATISTICS;

CHELATING AGENT; DEFEROXAMINE; FERRITIN;

ADOLESCENT; ADULT; AGE FACTORS; BETA-THALASSEMIA; CHELATING AGENTS; CHILD; CHILD, PRESCHOOL; DEFEROXAMINE; ETHNIC GROUPS; FEMALE; FERRITINS; GERMANY; HEMOSIDEROSIS; HUMANS; INCIDENCE; INFANT; MALE; PLASMAPHERESIS;

EID: 0032696040     PISSN: 03008630     EISSN: None     Source Type: Journal    
DOI: 10.1055/s-2008-1043828     Document Type: Review

References (25)

1. 1 Borgna-Pignatti, C., M. G. Zurlo, P. DeStefano, C. Boffa, V. DeSanctis, A. DiPalma, L. DiGregorio, C. Melevendi, A. Piga, V. Sabato: Outcome of thalassemia treated with conventional therapy. Bone marrow transpl. 12 Suppl. 1 (1993) 2-4
2. 2 Brittenham, G. M., P. M. Griffith, A. W. Nienhuis, C. E. McLaren, N. S. Young, E. E. Tucker, C. J. Allen, D. E. Farrell, J. W. Harris: Efficacy of deferoxamine in preventing complications of iron overload in patients with thalassemia major. N. Engl. J. Med 331 (1994) 567-573
3. 3 Cao, A., R. Galanello, M. C. Rosatelli, F. Argiolu, S. De Virgilüs: Clinical experience of management of thalassemia: The Sardinien experience. Semin. Hem. 33 (1996) 66-75
4. 4 Cohen, A., M. Martin, E. Schwartz: Response to long-term deferoxamine therapy in thalassemia. J. Pediatr. 99 (1981) 689
5. 5 Cohen, A., M. Martin, E. Schwartz: Current treatment of Cooley's Anemia. Intravenous chelation therapy. Ann. NY. Acad. Sci. 612 (1990) 286-292
6. 6 De Sanctis, V., C. Vullo, B. Bagni, L. Chiccoli: Hypoparathyroidism in beta-thalassemia major. Acta Haematol. 88 (1992) 105-108
7. 7 Ehlers, K. H., P. J. Giardina, M. L. Lesser, M. A. Engle, M. W. Hilgartner: Prolonged survival in patients with beta-thalassemia major treated with deferoxamine. J. Pediatr. 118 (1991) 540-545
8. 8 Fosburg, M. T., D. G. Nathan: Treatment of Cooley's anemia. Blood 76 (1990) 435-444
9. 9 Giardina, P. J., R. M. Grady, K. M. Ehlers, S. Burstein, R. H. Graziano, A. L. Markenson, M. W. Hilgartner: Current therapy of Cooley's anemia. A decade of experience with subcutaneous desferrioxamine. Ann. NY Acad. Sci. 612 (1990) 275-285
10. 10 Giardina, P. J., R. W. Grady: Chelation therapy in β-thalassaemia: The benefits and limitations of desferrioxamine. Semin. Hem. 32 (1995) 304-312
11. 11 Hershko, C., A. Pinson, G. Link: Iron chelation. Blood Rev. 4 (1990) 1-8
12. 12 Italian Working Group on Endocrine Complications in Non-endocrine Diseases: Multicentre study on prevalence of endocrine complications in thalassaemia major. Clin. Endocrinol. 42 (1995) 581-586
13. 13 Koch, D. A., P. J. Giardina, M. Ryan, K. N. MacQueen, M. W. Hilgartner: Behavioral contracting to improve adherence in patients with thalassemia. J. Pediatr. Nurs. 8 (1993) 106-111
14. 14 Kohne, E., K. Stahnke, A. E. Kulozik, E. Kleihauer: Multizentrische deutsche Thalassämie Studie. Konzept und erste Ergebnisse. Klin. Pädiatr. 204 (1992) 258-263
15. 15 Maurer, H. S., J. D. Lloyd-Still, C. Ingrisano, F. Gonzales-Crussi, G.R. Honig: A prospective evaluation of iron chelation therapy in children with severe β-thalassemia. A six year study. Amer. J. Dis. Child. 142 (1988) 287-292
16. 16 Olivieri, N. F., A. McGee, P. Liu, G. Koren, M. H. Freedman, L. Benson: Cardiac disease free survival in patients with thalassemia major treated with subcutaneous deferoxamine. An update of the Toronto cohort. Ann. NY Acad. Sci. 612 (1990) 585
17. 17 Olivieri, N. F., D. G. Nathan, J. H. McMillan, A. S. Wayne, P. Liu, A. Mc Gee, M. Martin, G. Koren, A. R. Cohen: Survival in medically treated patients with homozygous β-thalassemia. N. Engl. J. Med. 331 (1994) 574-578
18. 18 Olivieri, N. F., G. M. Brittenham: Iron-chelating therapy and the treatment of thalassemia. Blood 89 (1997) 739-761
19. 19 Pearson, H. A., Guiollotis, D. K, L. Rink, J. A. Wells: Patients age distribution in thalassemia major: Changes from 1973 to 1985. Pediatrics 80 (1987) 53-57
20. 20 Porter, J. B., R. D. Abeysinghe, L. Marshall, R. C. Hider, S. Singh: Kinetics of removal and reappearance of non-transferrin-bound plasma iron with deferoxamine therapy. Blood 88 (1996) 705-713
21. 21 Propper, R. D., L. N. Button, D. G. Nathan: New approaches to the transfusion management of thalassemia. Blood 55 (1980) 55-60
22. 22 Schwarz, C., B. Vener, E. Kohne, A. E. Kulozik: β-Thalassamie in Deutschland: Molekulargenetik und klinischer Phänotyp in der zuge-wanderten und in der cinheimischen Bevölkerung. Klin. Päd. 209 (1997) 172-177
23. 23 Stavroula, B.: Noncompliance with iron chelation therapy in patients with β-thalassaemia. J. Psychosom. Res. 33 (1989) 739-745
24. 24 Vetter, B., C. Schwarz, E. Kohne, A. E. Kulozik: β-Thalassaemia in the immigrant and in the non-immigrant German population. Br. J. Haematol. 97 (1997) 266-272
25. 25 Zurlo, M. G., P. De Stefano, C. Borgna-Pignatti, A. Di Palma, A. Piga, C. Melevendi, F. Di Gregorio, M. G. Burattini, S. Terzoli: Survival and cause of death in thalassaemia major. Lancet 2 (1989) 27-30